Abstract
To the Editor COVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors...
MeSH terms
-
COVID-19 / complications
-
COVID-19 / immunology*
-
COVID-19 / mortality
-
COVID-19 / physiopathology
-
Cardiovascular Diseases / complications
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / prevention & control*
-
Deprescriptions
-
Heart Disease Risk Factors*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / complications
-
Hyperlipidemias / drug therapy*
-
Hypolipidemic Agents / therapeutic use*
-
Primary Prevention
-
SARS-CoV-2
-
Secondary Prevention
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents